Literature DB >> 12126574

Relaxins: lessons and limitations.

James R Seibold1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12126574     DOI： 10.1007/s11926-002-0029-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  7 in total

Review 1.  [Treatment of systemic sclerosis].

Authors:  F H J van den Hoogen
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

2.  An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.

Authors:  Magalys Vitiello; Adriana Abuchar; Néstor Santana; Luis Dehesa; Francisco A Kerdel
Journal:  J Clin Aesthet Dermatol       Date:  2012-07

Review 3.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

4.  Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis.

Authors:  Y-C Lin; Y K Sung; X Jiang; M Peters-Golden; M R Nicolls
Journal:  Am J Transplant       Date:  2016-12-05       Impact factor: 8.086

Review 5.  Antifibrosis: to reverse the irreversible.

Authors:  Ziv Paz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 6.  Relaxin and its role in the development and treatment of fibrosis.

Authors:  Robert G Bennett
Journal:  Transl Res       Date:  2009-04-22       Impact factor: 7.012

Review 7.  Novel Anti-fibrotic Therapies.

Authors:  Benita L McVicker; Robert G Bennett
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.